Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04085029 · ClinicalTrials.gov registry record
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
A clinical trial of Metastatic Cancer and Oligometastasis, sponsored by Duke University.
- Recruiting
- Registry status
- 300
- Enrollment target
- 5
- Study locations
NCT04085029 is a study of Metastatic Cancer and Oligometastasis that is actively recruiting participants, run by Duke University. The registered enrollment target is 300 participants, below the 441-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (32% lower). The trial reports 5 study locations across 1 state.
The verdict
NCT04085029, a study of Metastatic Cancer and Oligometastasis, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.
Conditions Studied
Study Locations (5)
North Carolina
- Duke Cancer Institute Cary - Cary
- Durham Veterans Administration Health Care System (DVAHCS) - Durham
- Duke University Medical Center - Durham
- Duke Women's Cancer Care Raleigh - Raleigh
- Duke Raleigh Hospital - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2019-09-26 |
| Est. Completion | 2029-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04085029
The ClinicalTrials.gov registry entry for NCT04085029 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 441-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (32% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT04085029 reports 5 study locations spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04085029 about?
NCT04085029 is a clinical study titled "Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry". The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.
What is the current status of trial NCT04085029?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2019-09-26. Estimated completion is 2029-09.
What conditions does trial NCT04085029 study?
This clinical trial studies the following conditions: Metastatic Cancer, Oligometastasis.
Who is sponsoring clinical trial NCT04085029?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04085029 being conducted?
This trial has 5 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating Disparities in Precision Oncology
RECRUITING
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RECRUITING · Phase 2
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.